• • • • • • • • • 14.4 12.0 12.6 12.4 12.8 57.6 60.9 53.6 54.7 52.5 For the three months ended ...

Cellebrite DI Ltd. (CLBT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.11, delivering a surprise of 83.33%. Over the last four quarters, the com ...

Cellebrite Announces First-Quarter 2024 Results ARR of $331.8 million, up 27% year-over-year; Q1 2024 revenue of $89.6 million, up 26% year-over-year primarily due to 29% growth in subscription revenue; Q1 2024 adjusted EBITDA of $17.6 million, 19.7% adjusted EBITDA margin TYSONS CORNER, VA and PETAH TIKVA, ISRAEL, May 23, 2024 – Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three months end ...

财务表现 - Cellebrite在2024年第一季度实现了ARR达到3.318亿美元，同比增长27%[1] - 第一季度2024年收入达到8,960万美元，同比增长26%，主要由于订阅收入增长了29%[1] - 第一季度2024年调整后的EBITDA为1,760万美元，调整后的EBITDA利润率为19.7%[1] - 公司在2024年第一季度的净亏损为71,372千美元，较去年同期的40,605千美元有所增加[20] - 公司在2024年第一季度的现金流量从经营活动中为10,041千美元，较去年同期的12,476千美元有所下降[20] - 公司在2024年第一季度的非GAAP净收入为16,866千美元，较去年同期的6,899千美元有显著增长[29] - Cellebrite DI Ltd.在2024年第一季度的调整后EBITDA为17,632千美元，较去年同期的7,304千美元有增长[30] 公司战略 - Cellebrite CEO表示，公司在2024年的良好表现主要得益于全球业务的进一步扩张，利润性改善以及战略进展[2] - Cellebrite在2024年第一季度推出了授权软件即服务产品，以支持联邦客户利用公司的SaaS解决方案[3] - Cellebrite任命David Gee为首席营销官，他将负责公司全球营销战略的执行[4] - Cellebrite DI Ltd.在2024年第一季度的营收为89,582千美元，较去年同期的71,234千美元有显著增长[20] - Cellebrite DI Ltd.在2024年第一季度的订阅服务收入为79,222千美元，较去年同期的61,282千美元有增长[23]

ARR of $331.8 million, up 27% year-over-year; Q1 2024 revenue of $89.6 million, up 26% year-over-year primarily due to 29% growth in subscription revenue; Q1 2024 adjusted EBITDA of $17.6 million, 19.7% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 23, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ:CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three months ending March 31, 2024. "Cellebrit ...

Monty Rakusen/DigitalVision via Getty Images Cellebrite (NASDAQ:CLBT) is an Israeli company providing a suite of digital investigative (DI) solutions for law enforcement, governments, and enterprises to collect, review, analyze, and manage data in the context of legal investigation. CLBT went public through a SPAC transaction in 2021. The stock traded within the $10-11 range during this time, but continued to decline and reach an all-time low of $3.9 in September 2022 upon missing its revenue guidance by qu ...

分组1 - Cellebrite DI Ltd. (CLBT) 是一家在 Business Services 领域表现出色的公司[1] - CLBT 的 Zacks Rank 为 2 (Buy)，分析师对其全年盈利预期上调了22.1%[3] - CLBT 今年迄今为止的回报率为27.9%，高于 Business Services 行业平均回报率9.5%[4] 分组2 - Viant Technology (DSP) 也是另一家在 Business Services 领域表现优异的公司，今年迄今回报率为54.7%[4] - Viant Technology 目前的 Zacks Rank 为 2 (Buy)，当前年度的每股收益预期较过去三个月增长了46.3%[5] 分组3 - CLBT 属于 Technology Services 行业，该行业今年迄今平均回报率为16.3%，CLBT 在年初回报率表现更佳[6] - 投资者应继续关注 CLBT 和 Viant Technology，这两家公司有望继续保持良好表现[7]

公司报告 - Cellebrite DI Ltd. (NASDAQ:CLBT)宣布已向美国证券交易委员会提交了截至2023年12月31日的年度报告[1] - Cellebrite的2023年度报告Form 20-F可在其网站的投资者关系部分和SEC网站上找到[2] - 股东可以通过联系公司的方式免费获取2023年度报告Form 20-F的纸质副本[3] - Cellebrite的使命是帮助客户保护和拯救生命，加速司法进程，并在全球社区中保护隐私[4]

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE S ...

Investors with an interest in Technology Services stocks have likely encountered both Vontier Corporation (VNT) and Cellebrite DI Ltd. (CLBT) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy ...